Tomasz Gąsior, M.D.
During the American College of Cardiology Congress and the main session of Late Breaking Clinical Trials in Atlanta, USA, on 6 April 2024, mr. Gąsior, M.D., together with his research team, also published two other articles in leading cardiology journals - Circulation (IF = 37.8) and Journal of the American College of Cardiology (IF = 24).
The results presented here represent the results of a large, international study evaluating the effect of the SGLT2 inhibitor empagliflozin on outcomes in patients after myocardial infarction. These reports may have important implications for recommendations for the prevention of heart failure in patients with myocardial infarction worldwide.
ARTICLES:
Congratulations on your success and we wish you the best of luck in your future work!
This is another success for a WSB University scientist. Research and teaching staff of WSB University have again been ranked among the best scientists in the prestigious international Ad Scientific Index 2024 ranking - MORE INFO
